Division of CV Medicine, Vanderbilt University, Nashville, TN, USA.
Prog Cardiovasc Dis. 2010 Sep-Oct;53(2):88-93. doi: 10.1016/j.pcad.2010.06.002.
Cardiac disease in patients with cancer is common and influences the longevity and quality of life both of patients in active treatment and of survivors of cancer. The disciplines of cardiology and oncology have increasingly recognized the benefits to patients of collaborating in the care of cancer patients with cardiac disease. This increased recognition arises from several factors: the aging population in which both cardiac and cancer diagnoses are common; the cellular and molecular therapeutic targets of newer medical treatments, and, in particular, the specific patient treatment choices and decisions that require careful, effective clinical interactions between these 2 disciplines. Responding to this need for an effective partnership between cardiology and oncology, the International CardiOncology Society was created and has set goals to develop and enhance our understanding and management of these clinical difficulties.
在癌症患者中,心脏疾病很常见,会影响正在积极治疗的患者以及癌症幸存者的寿命和生活质量。心脏病学和肿瘤学领域越来越认识到,在治疗患有心脏疾病的癌症患者时,合作对患者有益。这种认识的提高源于几个因素:心血管和癌症诊断都很常见的老年人口;新型医疗治疗的细胞和分子治疗靶点,特别是需要这两个学科之间进行仔细、有效的临床互动的特定患者治疗选择和决策。为了应对心脏病学和肿瘤学之间建立有效伙伴关系的需求,成立了国际心脏肿瘤学会(International CardiOncology Society),并设定了目标,以发展和增强我们对这些临床难点的理解和管理。